Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240208 | 0.91 | PKM (0.63) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4785963 | 0.88 | PKM (0.63) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4233787 | 0.87 | PKM (0.56) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4226776 | 0.86 | PKM (0.54) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4240206 | 0.86 | PKM (0.60) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL13699119 | 0.85 | TAS1R3 (0.52) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4240960 | 0.84 | PKM (0.58) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4744588 | 0.84 | PKM (0.57) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4234355 | 0.83 | TAS1R3 (0.57) | PKMTAS1R3TAS1R1POLBMAPK1 | |
| SCHEMBL4229012 | 0.82 | PKM (0.50) | PKMTAS1R3TAS1R1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.